Nuveen LLC Buys Shares of 647,089 Humana Inc. (NYSE:HUM)

Key Points

• Nuveen LLC acquired a new stake in Humana Inc., purchasing 647,089 shares valued at approximately $171.22 million.
• Humana's latest quarterly earnings report showed $6.27 EPS, falling short of analysts' expectations, with revenues of $32.39 billion, surpassing estimates.
• Given recent analyst ratings, Humana holds a consensus rating of "Hold" with a price target averaging $281.62.

Nuveen LLC bought a new stake in Humana Inc. (NYSE:HUM - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 647,089 shares of the insurance provider's stock, valued at approximately $171,220,000. Nuveen LLC owned approximately 0.54% of Humana at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Virtu Financial LLC increased its holdings in Humana by 22.1% in the first quarter. Virtu Financial LLC now owns 4,517 shares of the insurance provider's stock valued at $1,195,000 after buying an additional 818 shares in the last quarter. Entropy Technologies LP purchased a new position in Humana in the first quarter valued at about $1,250,000. Frank Rimerman Advisors LLC increased its holdings in Humana by 17.2% in the first quarter. Frank Rimerman Advisors LLC now owns 1,732 shares of the insurance provider's stock valued at $458,000 after buying an additional 254 shares in the last quarter. MUFG Securities EMEA plc purchased a new position in Humana in the first quarter valued at about $9,790,000. Finally, Cynosure Group LLC increased its holdings in Humana by 11.6% in the first quarter. Cynosure Group LLC now owns 1,317 shares of the insurance provider's stock valued at $348,000 after buying an additional 137 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Up 0.2%

Shares of HUM opened at $267.19 on Tuesday. The firm has a market cap of $32.13 billion, a PE ratio of 20.51, a price-to-earnings-growth ratio of 1.57 and a beta of 0.44. The company's fifty day moving average is $238.61 and its two-hundred day moving average is $253.70. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $382.72. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the business earned $6.96 EPS. Analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on HUM shares. Wall Street Zen cut shares of Humana from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Morgan Stanley cut their price objective on Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a research report on Thursday, July 31st. Raymond James Financial upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a research report on Thursday, May 1st. Bank of America cut their price objective on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research report on Tuesday, June 17th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $290.00 price objective on shares of Humana in a research report on Thursday, May 1st. Seventeen research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $281.62.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.